Zeltia Group

Zeltia Group: Report at 31 March 2005

Madrid (ots/PRNewswire) - PharmaMar: - Zalypsis: this is PharmaMar's fifth compound to reach clinical development. - Aplidin: commenced Phase II studies on prostate and bladder cancer. - Yondelis: pivotal Phase III studies commenced on ovarian cancer patients. NeuroPharma: - Presented pre-clinical data at the 7th International Conference on Alzheimer's and Parkinson's Disease. Other: - Investment in R&D amounted to 8.9 million euro in the first quarter. - Group short- and long-term debt was similar to December 2004. - Net cash consumption was 3.8 million euro in the first quarter. ots Originaltext: Zeltia Group Im Internet recherchierbar: http://www.presseportal.ch Contact: Isabel Lozano, CEO, PHARMAMAR, S.A., C/ Reyes, 1.Colmenar Viejo, Madrid, Telephone +34-91-846-60-00; Catherine Moukheibir, Head of Capital Market Strategy, ZELTIA, S.A., José Abascal, 2. Madrid, Telephone +34-91-444-45-00; Ma. Luisa de Francia, CFO, ZELTIA, S.A., José Abascal, 2. Madrid, Telephone +34-91-444-45-00

Das könnte Sie auch interessieren: